keyword
MENU ▼
Read by QxMD icon Read
search

First generation antipsychotics

keyword
https://www.readbyqxmd.com/read/29316009/excess-incidence-and-risk-factors-for-recurrent-pneumonia-in-bipolar-disorder
#1
Min-Shan Li, Galen Chin-Lun Hung, Shu-Yu Yang, Chun-Hung Pan, Ya-Tang Liao, Shang-Ying Tsai, Chiao-Chicy Chen, Chian-Jue Kuo
AIM: Patients with bipolar disorder had poorer outcomes after pneumonia and could have a higher risk for recurrence of pneumonia. We aimed to investigate the incidence and risk factors of recurrent pneumonia in patients with bipolar disorder. METHODS: In a nationwide cohort of bipolar patients (derived from the National Health Insurance Research Database in Taiwan) who were hospitalized for pneumonia between 1996 and 2012, we identified 188 patients who developed recurrent pneumonia after a baseline pneumonia episode...
January 8, 2018: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29313261/enhancement-of-in-vivo-efficacy-and-oral-bioavailability-of-aripiprazole-with-solid-lipid-nanoparticles
#2
Silki, Vivek Ranjan Sinha
Aripiprazole (ARP), a second-generation or atypical antipsychotic, is poorly soluble and undergoes extensive hepatic metabolism and P-glycoprotein efflux which lead to reduced in vivo efficacy and increased dose-related side effects. To enhance in vivo efficacy and oral bioavailability of aripiprazole, aripiprazole-loaded solid lipid nanoparticles (SLNs) were developed using tristearin as solid lipid. Tween 80 and sodium taurocholate were used as surfactants to prepare SLNs using microemulsification method...
January 8, 2018: AAPS PharmSciTech
https://www.readbyqxmd.com/read/29303801/intravenous-valproic-acid-add-on-therapy-in-acute-agitation-adolescents-with-suspected-substance-abuse-a-report-of-six-cases
#3
Claudia Battaglia, Roberto Averna, Milena Labonia, Assia Riccioni, Stefano Vicari
The aim of this study was to test efficacy and safety of intravenous (IV) valproate for aggression in children and adolescents with mood or conduct disorder and concomitant substance abuse. Six patients received a 20 mg/kg dose of IV valproic acid as an add-on therapy to their standard therapy with second-generation antipsychotics and benzodiazepines. Agitation and general psychopathology were measured at baseline and after the first injection using the Modified Overt Aggression Scale, the Brief Psychiatric Rating Scale, and the Children's Global Assessment Scale...
January 5, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29299193/quetiapine-reverses-paclitaxel-induced-neuropathic-pain-in-mice-role-of-alpha2-adrenergic-receptors
#4
Alireza Abed, Mohammad Javad Khoshnoud, Mehdi Taghian, Mahbubeh Aliasgharzadeh, Azam Mesdaghinia
Objectives: Paclitaxel-induced peripheral neuropathy is a common adverse effect of cancer chemo -therapy. This neuropathy has a profound impact on quality of life and patient's survival. Preventing and treating paclitaxel-induced peripheral neuropathy is a major concern. First- and second-generation antipsychotics have shown analgesic effects both in humans and animals. Quetiapine is a novel atypical antipsychotic with low propensity to induce extrapyramidal or hyperprolactinemia side effects...
November 2017: Iranian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/29297696/second-generation-antipsychotics-in-adolescent-psychiatric-patients-metabolic-effects-and-impact-of-an-early-weight-change-to-predict-longer-term-weight-gain
#5
Frederik Vandenberghe, Alexandra Najar-Giroud, Laurent Holzer, Philippe Conus, Chin B Eap, Anne-Emmanuelle Ambresin
OBJECTIVES: To examine the metabolic profile of adolescents at baseline and to determine the potential predictive power of a 1-month weight gain (WG) on weight changes during longer term second-generation antipsychotic (SGA) treatment. METHODS: A retrospective chart review study, including patients between 13 and 18 years of age and treated with SGA, was conducted. Available data at baseline, 1, 3, and 12 months of treatment were recorded. RESULTS: Four hundred fifty-six patients were included, with a median age of 15 years...
January 3, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29274734/antipsychotics-and-mortality-in-a-nationwide-cohort-of-29-823-patients-with-schizophrenia
#6
Heidi Taipale, Ellenor Mittendorfer-Rutz, Kristina Alexanderson, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Jari Tiihonen
INTRODUCTION: It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients with schizophrenia, and if there are any clinically meaningful differences between specific agents and routes of administration. METHODS: We linked prospectively gathered nationwide register-based data during 2006-2013 to study all-cause mortality among all patients aged 16-64years with schizophrenia in Sweden (N=29,823 in total; N=4603 in the incident cohort)...
December 20, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29273271/clozapine-use-in-patients-with-schizophrenia-and-a-comorbid-substance-use-disorder-a-systematic-review
#7
REVIEW
Belén Arranz, Marina Garriga, Clemente García-Rizo, Luis San
Lifetime prevalence of substance use disorders (SUD) in patients with schizophrenia is nearly 50%. Nicotine, alcohol, and cannabis are the substances most frequently used, with a high percentage of poly-substance users. There are few available data about pharmacological approaches in this population. Amongst antipsychotics, clozapine shows positive evidence in the literature. The aim of the present article is to provide systematic review on the efficacy of clozapine in SUD improvement in schizophrenic patients...
December 19, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29224570/mapping-the-evidence-on-pharmacological-interventions-for-non-affective-psychosis-in-humanitarian-non-specialised-settings-a-unhcr-clinical-guidance
#8
Giovanni Ostuzzi, Corrado Barbui, Charlotte Hanlon, Sudipto Chatterjee, Julian Eaton, Lynne Jones, Derrick Silove, Peter Ventevogel
BACKGROUND: Populations exposed to humanitarian emergencies are particularly vulnerable to mental health problems, including new onset, relapse and deterioration of psychotic disorders. Inadequate care for this group may lead to human rights abuses and even premature death. The WHO Mental Health Gap Action Programme Intervention Guide (mhGAP-IG), and its adaptation for humanitarian settings (mhGAP-HIG), provides guidance for management of mental health conditions by non-specialised healthcare professionals...
December 11, 2017: BMC Medicine
https://www.readbyqxmd.com/read/29182611/the-differential-effects-of-neuroleptic-drugs-and-pacap-on-the-expression-of-bdnf-mrna-and-protein-in-a-human-glioblastoma-cell-line
#9
Marta Jóźwiak-Bębenista, Magdalena Jasińska-Stroschein, Edward Kowalczyk
Despite numerous studies, the molecular mechanisms underpinning the action of antipsychotic drugs remain not fully understood. It has been suggested that, in addition to the modulation of monoaminergic neurotransmission, antipsychotic drugs can also affect the expression of neurotrophic factors in the brain. The present study examines the effects of a first-generation neuroleptic drug (FGA; haloperidol) and two second-generation neuroleptic drugs (SGAs; olanzapine and amisulpride) on the expression and levels of brain-derived neurotrophic factor (BDNF) in an astrocyte-like T98G glioblastoma cell line...
2017: Acta Neurobiologiae Experimentalis
https://www.readbyqxmd.com/read/29175720/t4-and-waist-hip-ratio-as-biomarkers-of-antipsychotic-induced-weight-gain-in-han-chinese-inpatients-with-schizophrenia
#10
Shen Li, Ying Gao, Hao Lv, Miaomiao Zhang, Lili Wang, Rui Jiang, Chengai Xu, Xueshi Wang, Ming Gao, Yukun He, Jie Li, Wei-Dong Li
Second-generation antipsychotic agents (SGAs) cause serious metabolic side effects, including weight gain, dyslipidemia, and glucose metabolism abnormalities, which occur by unknown mechanisms. Therefore, the search for prospective markers for antipsychotic-induced weight gain (AIWG) has been of major interest. So far, predictive factors predisposing patients to the develop obesity and related metabolic disturbances induced by SGAs have been relatively less studied among large samples of Chinese schizophrenic patients...
November 21, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/29168795/antipsychotic-polypharmacy-among-children-and-young-adults-in-office-based-or-hospital-outpatient-department-settings
#11
Minji Sohn, Meghan Burgess, Mohamed Bazzi
The purpose of the study was three-fold: (1) to estimate the national trends in antipsychotic (AP) polypharmacy among 6- to 24-year-old patients in the U.S.; (2) to identify frequently used AP agents and mental disorder diagnoses related to AP polypharmacy; and (3) to assess the strength of association between AP polypharmacy and patient/provider characteristics. We used publicly available ambulatory health care datasets to evaluate AP polypharmacy in office-based or hospital outpatient department settings to conduct a cross-sectional study...
November 23, 2017: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/29168261/-impact-of-drug-reimbursement-policies-on-prescribing-a-case-study-of-a-newly-marketed-long-acting-injectable-antipsychotics-among-relapsed-schizophrenia-patients
#12
John W Jackson, Lisa Fulchino, James Rogers, Helen Mogun, Jennifer Polinski, David C Henderson, Sebastian Schneeweiss, Michael A Fischer
OBJECTIVE: To quantify and explain variation in use of long-acting injectable antipsychotics (LAIs) in the United States, and understand the relationship between patient characteristics, drug reimbursement policies, and LAI prescribing after relapse. METHODS: A cohort of recently relapsed patients with schizophrenia ages 18 to 64, identified immediately after discharge from a related inpatient hospitalization, partial hospitalization, or emergency room visit, drawn from 2004 to 2006 Medicaid claims, and followed for 90 days until LAI initiation...
November 23, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29145545/treatment-of-alcohol-induced-psychotic-disorder-alcoholic-hallucinosis-a-systematic-review
#13
Barkat Masood, Peter Lepping, Dmitry Romanov, Rob Poole
Aims: To evaluate the effectiveness of evidence based treatments for alcohol-induced psychotic disorder (AIPD) as described by ICD-10 and DSM-5, a condition that is distinct from schizophrenia and has a close relationship with alcohol withdrawal states. Method: Systematic review using PRISMA guidelines. Results: Of 6205 abstracts found, fifteen studies and ten case reports met criteria and were examined. Larger studies examined the use of first-generation antipsychotic drugs, reporting full or partial remission in most patients...
November 14, 2017: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/29132553/dysregulation-of-glucose-metabolism-since-young-adulthood-increases-the-risk-of-cardiovascular-diseases-in-patients-with-bipolar-disorder
#14
Pao-Huan Chen, Yen-Kuang Lin, Chi-Kang Chang, Shuo-Ju Chiang, Shang-Ying Tsai
Aging patients with bipolar disorder (BD) are at a high risk of cardiovascular diseases (CVDs). However, few studies have directly examined the association between metabolic risks and CVDs in patients with BD across the lifespan. Therefore, the aim of this study was to determine lifetime metabolic risk factors for CVDs in patients with BD. We recruited BD-I patients who were more than 50 years old and had had at least one psychiatric hospitalization. Patients who had a cardiologist-confirmed CVD diagnosis (ICD-9 code 401-414) were assigned to the case group...
December 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/29114100/successful-treatment-of-severe-tardive-dyskinesia-with-valbenazine-including-a-patient-s-perspective
#15
Richard C Josiassen, Dawn M Filmyer, Jack Gillean, Syed Sikandar Shah, Tyler E Dietterich, Rita A Shaughnessy
BACKGROUND Tardive dyskinesia (TD) is a chronic involuntary movement disorder frequently induced by dopamine receptor blockers, particularly first-generation antipsychotics. Until recently, management of TD was restricted to lowering the dose of the current medication, switching to another medication, or using off-label treatments with insufficient evidence of efficacy. Valbenazine, a vesicular monoamine transporter-2 (VMAT2) inhibitor, became the first drug to be approved by the FDA specifically for the treatment of TD...
November 8, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29110139/the-place-of-antipsychotics-in-the-therapy-of-anxiety-disorders-and-obsessive-compulsive-disorders
#16
REVIEW
Baptiste Pignon, Chloé Tezenas du Montcel, Louise Carton, Antoine Pelissolo
PURPOSE OF REVIEW: The purpose of this review was to assess and present the findings up to this date on the efficacy of antipsychotics in the treatment of generalized anxiety disorders (GAD), social anxiety disorders (SAD), panic disorders (PD), and obsessive-compulsive disorders (OCD), mostly based on published randomized controlled trials (RCTs) or on open-label studies when RCT were lacking. RECENT FINDINGS: Quetiapine could be recommended in patients with GAD...
November 7, 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29107449/risk-of-gastrointestinal-hypomotility-in-schizophrenia-and-schizoaffective-disorder-treated-with-antipsychotics-a-retrospective-cohort-study
#17
Hsing-Kang Chen, Chia-Jung Hsieh
OBJECTIVE: The risk of gastrointestinal hypomotility (GIHM) with the use of antipsychotic medications in patients with schizophrenia remains inadequately recognized. The aim of this study was to explore the incidence of GIHM and its risks in patients with schizophrenia treated with antipsychotics. METHODS: We conducted a retrospective cohort study using the National Health Insurance Research Database. We identified adult (≥ 20years of age) patients with a first-time diagnosis of schizophrenia or schizoaffective disorder in the Registry for Catastrophic Illness Patients during the period from 2001 to 2011...
October 27, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29105246/role-of-potentially-inappropriate-medication-use-in-rehabilitation-outcomes-for-geriatric-patients-after-strokes
#18
Eiji Kose, Toshiyuki Hirai, Toshiichi Seki, Hiroyuki Hayashi
AIM: The effect of the use of potentially inappropriate medications (PIM) on mortality and functional outcome after strokes is unclear in Japan. The aim of the present study was to establish whether treatment with PIM affects functional improvements among geriatric patients convalescing after strokes. METHODS: This retrospective longitudinal study included consecutive geriatric patients admitted and discharged from convalescent rehabilitation wards for stroke between 2010 and 2016...
November 3, 2017: Geriatrics & Gerontology International
https://www.readbyqxmd.com/read/29093685/bipolar-spectrum-disorders-in-male-youth-the-interplay-between-symptom-severity-inflammation-steroid-secretion-and-body-composition
#19
REVIEW
Andreas Walther, Marlene Penz, Daniela Ijacic, Timothy R Rice
The morbidity and societal burden of youth bipolar spectrum disorders (BSD) are high. These disorders are multisystemic in that adult populations there are clear interactions with inflammatory processes and steroidal physiological systems. There are much less data concerning these areas of study in youth populations with BSD. This is surprising given the association of youth-onset BSD with puberty and its associated physiological changes. In this mini-review, we overview the theoretical role of inflammatory processes and steroidal physiological systems in youth BSD, describe the greater literature in adult populations, detail the literature in youth populations when available, and overview current proposed molecular mechanistic pathways and interaction effects based on the available data...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29075885/long-term-metabolic-effects-of-aripiprazole-ziprasidone-and-quetiapine-a-pragmatic-clinical-trial-in-drug-na%C3%A3-ve-patients-with-a-first-episode-of-non-affective-psychosis
#20
Javier Vázquez-Bourgon, Rocío Pérez-Iglesias, Víctor Ortiz-García de la Foz, Paula Suárez Pinilla, Álvaro Díaz Martínez, Benedicto Crespo-Facorro
INTRODUCTION: The use of second-generation antipsychotics (SGA) has been associated with metabolic changes. However, there are differences in the metabolic profile between SGAs. We have previously observed that ziprasidone had a more benign early metabolic profile compared to aripiprazole and quetiapine. However, a long-term follow-up is preferred to detect clinically relevant impairment in metabolic parameters. We aimed to compare the effect of aripiprazole, ziprasidone, and quetiapine on metabolic measures in first-episode non-affective psychosis patients after 1 year of treatment...
January 2018: Psychopharmacology
keyword
keyword
97706
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"